UPDATE: UBS Downgrades Celgene (CELG) to Neutral: Taking Some Off The Table
Tweet Send to a FriendGet Alerts CELG Hot Sheet
Price: $124.91 +1.16%
Rating Summary:
19 Buy, 9 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
19 Buy, 9 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade CELG Now!
(Updated - September 10, 2012 12:26 PM EDT)
UBS downgraded Celgene (NASDAQ: CELG) from Buy to Neutral. PT raised $2 to $80.
Analyst, Matthew Roden, said, "CELG shares are up 27% since Revlimid was not approved in the EU (S&P: +8%), at which time we argued upcoming apremilast data represented a catalyst for re-rating. That having played out, we see the risk-reward as more balanced at current levels, and view CELG as a stock we’d rather add on pullbacks, such as those created from the second cancer controversy or the Revlimid EU non-approval. See our accompanying industry note for our updated views on the sector."
FY13 EPS estimate lowered from $5.53 to $5.46.
For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.
Shares of Celgene closed at $75.44 yesterday, with a 52 week range of $58.53-$80.42.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
UBS downgraded Celgene (NASDAQ: CELG) from Buy to Neutral. PT raised $2 to $80.
Analyst, Matthew Roden, said, "CELG shares are up 27% since Revlimid was not approved in the EU (S&P: +8%), at which time we argued upcoming apremilast data represented a catalyst for re-rating. That having played out, we see the risk-reward as more balanced at current levels, and view CELG as a stock we’d rather add on pullbacks, such as those created from the second cancer controversy or the Revlimid EU non-approval. See our accompanying industry note for our updated views on the sector."
FY13 EPS estimate lowered from $5.53 to $5.46.
For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.
Shares of Celgene closed at $75.44 yesterday, with a 52 week range of $58.53-$80.42.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Deutsche Bank Takes Aegerion (AEGR) Price Target from $52 to $85
- Jefferies Downgrades Limited Brands (LTD) to Underperform; Sees 21% Downside
Create E-mail Alert Related Categories
Analyst EPS Change, Analyst EPS View, Analyst PT Change, DowngradesRelated Entities
UBS, Standard & Poor's
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
